<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37234102</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2314-7156</ISSN><JournalIssue CitedMedium="Internet"><Volume>2023</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Journal of immunology research</Title><ISOAbbreviation>J Immunol Res</ISOAbbreviation></Journal><ArticleTitle>Protein Phosphatase 2A: Role in T Cells and Diseases.</ArticleTitle><Pagination><StartPage>4522053</StartPage><MedlinePgn>4522053</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">4522053</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1155/2023/4522053</ELocationID><Abstract><AbstractText>Protein phosphatase 2A (PP2A) is a serine-threonine phosphatase that plays an important role in the regulation of cell proliferation and signal transduction. The catalytic activity of PP2A is integral in the maintenance of physiological functions which gets severely impaired in its absence. PP2A plays an essential role in the activation, differentiation, and functions of T cells. PP2A suppresses Th1 cell differentiation while promoting Th2 cell differentiation. PP2A fosters Th17 cell differentiation which contributes to the pathogenesis of systemic lupus erythematosus (SLE) by enhancing the transactivation of the <i>Il17</i> gene. Genetic deletion of PP2A in Tregs disrupts Foxp3 expression due to hyperactivation of mTORC1 signaling which impairs the development and immunosuppressive functions of Tregs. PP2A is important in the induction of Th9 cells and promotes their antitumor functions. PP2A activation has shown to reduce neuroinflammation in a mouse model of experimental autoimmune encephalomyelitis (EAE) and is now used to treat multiple sclerosis (MS) clinically. In this review, we will discuss the structure and functions of PP2A in T cell differentiation and diseases and therapeutic applications of PP2A-mediated immunotherapy.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Suyasha Roy and Lalit Batra.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Roy</LastName><ForeName>Suyasha</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0332-4962</Identifier><AffiliationInfo><Affiliation>Immuno-Biology Laboratory, Translational Health Science and Technology Institute, Faridabad, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Molecular Immunology, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Batra</LastName><ForeName>Lalit</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-4375-9004</Identifier><AffiliationInfo><Affiliation>Regional Biocontainment Laboratory, Center for Predictive Medicine, University of Louisville, Louisville, KY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Egypt</Country><MedlineTA>J Immunol Res</MedlineTA><NlmUniqueID>101627166</NlmUniqueID><ISSNLinking>2314-7156</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.1.3.16</RegistryNumber><NameOfSubstance UI="D054648">Protein Phosphatase 2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054648" MajorTopicYN="N">Protein Phosphatase 2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004681" MajorTopicYN="Y">Encephalomyelitis, Autoimmune, Experimental</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018417" MajorTopicYN="N">Th1 Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018418" MajorTopicYN="N">Th2 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>26</Day><Hour>13</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>26</Day><Hour>12</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37234102</ArticleId><ArticleId IdType="pmc">PMC10208765</ArticleId><ArticleId IdType="doi">10.1155/2023/4522053</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Manning G., Whyte D. B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science . 2002;298(5600):1912&#x2013;1934. doi: 10.1126/science.1075762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1075762</ArticleId><ArticleId IdType="pubmed">12471243</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso A., Sasin J., Bottini N., et al. Protein tyrosine phosphatases in the human genome. Cell . 2004;117(6):699&#x2013;711. doi: 10.1016/j.cell.2004.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2004.05.018</ArticleId><ArticleId IdType="pubmed">15186772</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshacharyulu P., Pandey P., Datta K., Batra S. K. Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. Cancer Letters . 2013;335(1):9&#x2013;18. doi: 10.1016/j.canlet.2013.02.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2013.02.036</ArticleId><ArticleId IdType="pmc">PMC3665613</ArticleId><ArticleId IdType="pubmed">23454242</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho U. S., Xu W. Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme. Nature . 2007;445:53&#x2013;57. doi: 10.1038/nature05351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature05351</ArticleId><ArticleId IdType="pubmed">17086192</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y. Serine/threonine phosphatases: mechanism through structure. Cell . 2009;139(3):468&#x2013;484. doi: 10.1016/j.cell.2009.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2009.10.006</ArticleId><ArticleId IdType="pubmed">19879837</ArticleId></ArticleIdList></Reference><Reference><Citation>Orgad S., Brewis N. D., Alphey L., Myles Axton J., Dudai Y., Cohen P. T. W. The structure of protein phosphatase 2A is as highly conserved as that of protein phosphatase I. FEBS Letters . 1990;275(1-2):44&#x2013;48. doi: 10.1016/0014-5793(90)81435-Q.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-5793(90)81435-Q</ArticleId><ArticleId IdType="pubmed">2175718</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan M. M., Kalim U. U., Khan M. H., Lahesmaa R. PP2A and its inhibitors in helper T-cell differentiation and autoimmunity. Frontiers in Immunology . 2022;12 doi: 10.3389/fimmu.2021.786857.786857</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.786857</ArticleId><ArticleId IdType="pmc">PMC8766794</ArticleId><ArticleId IdType="pubmed">35069561</ArticleId></ArticleIdList></Reference><Reference><Citation>Meidan E., Li H., Pan W., et al. Serine/threonine phosphatase PP2A is essential for optimal B cell function. JCI Insight . 2020;5(5) doi: 10.1172/jci.insight.130655.e130655</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.130655</ArticleId><ArticleId IdType="pmc">PMC7141385</ArticleId><ArticleId IdType="pubmed">32161189</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y., Xing Y., Chen Y., et al. Structure of the protein phosphatase 2A holoenzyme. Cell . 2006;127(6):1239&#x2013;1251. doi: 10.1016/j.cell.2006.11.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2006.11.033</ArticleId><ArticleId IdType="pubmed">17174897</ArticleId></ArticleIdList></Reference><Reference><Citation>Longin S., Zwaenepoel K., Louis J. V., Dilworth S., Goris J., Janssens V. Selection of protein phosphatase 2A regulatory subunits is mediated by the C terminus of the catalytic Subunit. Journal of Biological Chemistry . 2007;282(37):26971&#x2013;26980. doi: 10.1074/jbc.M704059200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M704059200</ArticleId><ArticleId IdType="pubmed">17635907</ArticleId></ArticleIdList></Reference><Reference><Citation>Leulliot N., Quevillon-Cheruel S., Sorel I., et al. Structure of protein phosphatase methyltransferase 1 (PPM1), a leucine carboxyl methyltransferase involved in the regulation of protein phosphatase 2A activity. Journal of Biological Chemistry . 2004;279(9):8351&#x2013;8358. doi: 10.1074/jbc.M311484200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M311484200</ArticleId><ArticleId IdType="pubmed">14660564</ArticleId></ArticleIdList></Reference><Reference><Citation>Damuni Z., Xiong H., Li M. Autophosphorylation-activated protein kinase inactivates the protein tyrosine phosphatase activity of protein phosphatase 2A. FEBS Letters . 1994;352(3):311&#x2013;314. doi: 10.1016/0014-5793(94)00981-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-5793(94)00981-3</ArticleId><ArticleId IdType="pubmed">7523189</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssens V., Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochemical Journal . 2001;353(3):417&#x2013;439. doi: 10.1042/bj3530417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bj3530417</ArticleId><ArticleId IdType="pmc">PMC1221586</ArticleId><ArticleId IdType="pubmed">11171037</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson R. T., Desai B. N., Hardwick J. S., Schreiber S. L. Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12&#x2014;rapamycinassociated protein. PNAS . 1999;96(8):4438&#x2013;4442. doi: 10.1073/pnas.96.8.4438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.96.8.4438</ArticleId><ArticleId IdType="pmc">PMC16350</ArticleId><ArticleId IdType="pubmed">10200280</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn K., Miranda M., Francis V. A., Vendrell J., Zorzano A., Teleman A. A. PP2A regulatory subunit PP2A-B&#x2019; counteracts S6K phosphorylation. Cell Metabolism . 2010;11(5):438&#x2013;444. doi: 10.1016/j.cmet.2010.03.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2010.03.015</ArticleId><ArticleId IdType="pubmed">20444422</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung H., Brautigan D. L. Protein phosphatase 2A suppresses MAP kinase signalling and ectopic protein expression. Cellular Signalling . 1999;11(8):575&#x2013;580. doi: 10.1016/S0898-6568(99)00033-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0898-6568(99)00033-9</ArticleId><ArticleId IdType="pubmed">10433518</ArticleId></ArticleIdList></Reference><Reference><Citation>Eitelhuber A. C., Warth S., Schimmack G., et al. Dephosphorylation of Carma1 by PP2A negatively regulates T-cell activation. The EMBO Journal . 2011;30(3):594&#x2013;605. doi: 10.1038/emboj.2010.331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2010.331</ArticleId><ArticleId IdType="pmc">PMC3034008</ArticleId><ArticleId IdType="pubmed">21157432</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo Y.-C., Huang K.-Y., Yang C.-H., Yang Y.-S., Lee W.-Y., Chiang C.-W. Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55&#x3b1; regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt. Journal of Biological Chemistry . 2008;283(4):1882&#x2013;1892. doi: 10.1074/jbc.M709585200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M709585200</ArticleId><ArticleId IdType="pubmed">18042541</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssens V., Rebollo A. The role and therapeutic potential of Ser/Thr phosphatase PP2A in apoptotic signalling networks in human cancer cells. Current Molecular Medicine . 2012;12(3):268&#x2013;287. doi: 10.2174/156652412799218930.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156652412799218930</ArticleId><ArticleId IdType="pubmed">22300139</ArticleId></ArticleIdList></Reference><Reference><Citation>Junttila M. R., Puustinen P., Niemel&#xe4; M., et al. CIP2A inhibits PP2A in human malignancies. Cell . 2007;130(1):51&#x2013;62. doi: 10.1016/j.cell.2007.04.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.04.044</ArticleId><ArticleId IdType="pubmed">17632056</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross J. A., Cheng H., Nagy Z. S., Frost J. A., Kirken R. A. Protein phosphatase 2A regulates interleukin-2 receptor complex formation and JAK3/STAT5 activation. Journal of Biological Chemistry . 2010;285(6):3582&#x2013;3591. doi: 10.1074/jbc.M109.053843.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.053843</ArticleId><ArticleId IdType="pmc">PMC2823499</ArticleId><ArticleId IdType="pubmed">19923221</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Yue P., Deng X., et al. Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E. Neoplasia . 2010;12(10):848&#x2013;855. doi: 10.1593/neo.10704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1593/neo.10704</ArticleId><ArticleId IdType="pmc">PMC2950334</ArticleId><ArticleId IdType="pubmed">20927323</ArticleId></ArticleIdList></Reference><Reference><Citation>Eichhorn P. J. A., Creyghton M. P., Bernards R. Protein phosphatase 2A regulatory subunits and cancer. Biochimica et Biophysica Acta (BBA)&#x2014;Reviews on Cancer . 2009;1795(1):1&#x2013;15. doi: 10.1016/j.bbcan.2008.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbcan.2008.05.005</ArticleId><ArticleId IdType="pubmed">18588945</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrotti D., Neviani P. Protein phosphatase 2A: a target for anticancer therapy. The Lancet Oncology . 2013;14(6):e229&#x2013;e238. doi: 10.1016/S1470-2045(12)70558-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(12)70558-2</ArticleId><ArticleId IdType="pmc">PMC3913484</ArticleId><ArticleId IdType="pubmed">23639323</ArticleId></ArticleIdList></Reference><Reference><Citation>Taffs R. E., Redegeld F. A., Sitkovsky M. V. Modulation of cytolytic T lymphocyte functions by an inhibitor of serine/threonine phosphatase, okadaic acid. Enhancement of cytolytic T lymphocyte-mediated cytotoxicity. The Journal of Immunology . 1991;147(2):722&#x2013;728. doi: 10.4049/jimmunol.147.2.722.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.147.2.722</ArticleId><ArticleId IdType="pubmed">1649222</ArticleId></ArticleIdList></Reference><Reference><Citation>Parry R. V., Chemnitz J. M., Frauwirth K. A., et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Molecular and Cellular Biology . 2005;25(21):9543&#x2013;9553. doi: 10.1128/MCB.25.21.9543-9553.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.25.21.9543-9553.2005</ArticleId><ArticleId IdType="pmc">PMC1265804</ArticleId><ArticleId IdType="pubmed">16227604</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P., Shaffer D. R., Alvarez Arias D. A., et al. In vivo discovery of immunotherapy targets in the tumour microenvironment. Nature . 2014;506:52&#x2013;57. doi: 10.1038/nature12988.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12988</ArticleId><ArticleId IdType="pmc">PMC4052214</ArticleId><ArticleId IdType="pubmed">24476824</ArticleId></ArticleIdList></Reference><Reference><Citation>Brownlie R. J., Zamoyska R. T cell receptor signalling networks: branched, diversified and bounded. Nature Reviews Immunology . 2013;13:257&#x2013;269. doi: 10.1038/nri3403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3403</ArticleId><ArticleId IdType="pubmed">23524462</ArticleId></ArticleIdList></Reference><Reference><Citation>Breuer R., Becker M. S., Brechmann M., Mock T., Arnold R., Krammer P. H. The protein phosphatase 2A regulatory subunit B56&#x3b3; mediates suppression of T cell receptor (TCR)-induced nuclear factor-&#x3ba;B (NF-&#x3ba;B) activity. Journal of Biological Chemistry . 2014;289(21):14996&#x2013;15004. doi: 10.1074/jbc.M113.533547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.533547</ArticleId><ArticleId IdType="pmc">PMC4031550</ArticleId><ArticleId IdType="pubmed">24719332</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosmann T. R., Cherwinski H., Bond M. W., Giedlin M. A., Coffman R. L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. The Journal of Immunology . 1986;136(7):2348&#x2013;2357. doi: 10.4049/jimmunol.136.7.2348.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.136.7.2348</ArticleId><ArticleId IdType="pubmed">2419430</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinchieri G., Pflanz S., Kastelein R. A. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity . 2003;19(5):641&#x2013;644. doi: 10.1016/S1074-7613(03)00296-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1074-7613(03)00296-6</ArticleId><ArticleId IdType="pubmed">14614851</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan M. H., Sun Y.-L., Hoey T., Grusby M. J. Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature . 1996;382:174&#x2013;177. doi: 10.1038/382174a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/382174a0</ArticleId><ArticleId IdType="pubmed">8700209</ArticleId></ArticleIdList></Reference><Reference><Citation>Thierfelder W. E., van Deursen J. M., Yamamoto K., et al. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature . 1996;382:171&#x2013;174. doi: 10.1038/382171a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/382171a0</ArticleId><ArticleId IdType="pubmed">8700208</ArticleId></ArticleIdList></Reference><Reference><Citation>Szabo S. J., Kim S. T., Costa G. L., Zhang X., Garrison Fathman C., Glimcher L. H. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell . 2000;100(6):655&#x2013;669. doi: 10.1016/S0092-8674(00)80702-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(00)80702-3</ArticleId><ArticleId IdType="pubmed">10761931</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J., Guo L., Watson C. J., Hu-Li J., Paul W. E. Stat6 is necessary and sufficient for IL-4&#x2019;s role in Th2 differentiation and cell expansion. The Journal of Immunology . 2001;166(12):7276&#x2013;7281. doi: 10.4049/jimmunol.166.12.7276.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.166.12.7276</ArticleId><ArticleId IdType="pubmed">11390477</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan M. H., Schindler U., Smiley S. T., Grusby M. J. Stat6 is required for mediating responses to IL-4 and for the development of Th2 cells. Immunity . 1996;4(3):313&#x2013;319. doi: 10.1016/S1074-7613(00)80439-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1074-7613(00)80439-2</ArticleId><ArticleId IdType="pubmed">8624821</ArticleId></ArticleIdList></Reference><Reference><Citation>Pai S.-Y., Truitt M. L., Ho I.-C. GATA-3 deficiency abrogates the development and maintenance of T helper type 2 cells. PNAS . 2004;101(7):1993&#x2013;1998. doi: 10.1073/pnas.0308697100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0308697100</ArticleId><ArticleId IdType="pmc">PMC357040</ArticleId><ArticleId IdType="pubmed">14769923</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy S., Rizvi Z. A., Awasthi A. Metabolic checkpoints in differentiation of helper T cells in tissue inflammation. Frontiers in Immunology . 2019;9 doi: 10.3389/fimmu.2018.03036.3036</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.03036</ArticleId><ArticleId IdType="pmc">PMC6340303</ArticleId><ArticleId IdType="pubmed">30692989</ArticleId></ArticleIdList></Reference><Reference><Citation>Delgoffe G. M., Kole T. P., Zheng Y., et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity . 2009;30(6):832&#x2013;844. doi: 10.1016/j.immuni.2009.04.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2009.04.014</ArticleId><ArticleId IdType="pmc">PMC2768135</ArticleId><ArticleId IdType="pubmed">19538929</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho W. S., Wang H., Maggio D., et al. Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade. Nature Communications . 2018;9 doi: 10.1038/s41467-018-04425-z.2126</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-04425-z</ArticleId><ArticleId IdType="pmc">PMC5974350</ArticleId><ArticleId IdType="pubmed">29844427</ArticleId></ArticleIdList></Reference><Reference><Citation>Woetmann A., Brockdorff J., Lovato P., et al. Protein phosphatase 2A (PP2A) regulates interleukin-4-mediated STAT6 signaling. Journal of Biological Chemistry . 2003;278(5):2787&#x2013;2791. doi: 10.1074/jbc.M210196200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M210196200</ArticleId><ArticleId IdType="pubmed">12426308</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangan P. R., Harrington L. E., O&#x2019;Quinn D. B., et al. Transforming growth factor-&#x3b2; induces development of the TH17 lineage. Nature . 2006;441:231&#x2013;234. doi: 10.1038/nature04754.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature04754</ArticleId><ArticleId IdType="pubmed">16648837</ArticleId></ArticleIdList></Reference><Reference><Citation>Veldhoen M., Hocking R. J., Atkins C. J., Locksley R. M., Stockinger B. TGF&#x3b2; in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity . 2006;24(2):179&#x2013;189. doi: 10.1016/j.immuni.2006.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2006.01.001</ArticleId><ArticleId IdType="pubmed">16473830</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai H., Gao X., Zhao L., et al. Respective IL-17A production by &#x3b3;&#x3b4; T and Th17 cells and its implication in host defense against chlamydial lung infection. Cellular &amp; Molecular Immunology . 2017;14:850&#x2013;861. doi: 10.1038/cmi.2016.53.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cmi.2016.53</ArticleId><ArticleId IdType="pmc">PMC5649107</ArticleId><ArticleId IdType="pubmed">27796286</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonian P. L., Roark C. L., Wehrmann F., et al. IL-17A-expressing T cells are essential for bacterial clearance in a murine model of hypersensitivity pneumonitis. The Journal of Immunology . 2009;182(10):6540&#x2013;6549. doi: 10.4049/jimmunol.0900013.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0900013</ArticleId><ArticleId IdType="pmc">PMC2766088</ArticleId><ArticleId IdType="pubmed">19414809</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong C. K., Lit L. C. W., Tam L. S., Li E. K. M., Wong P. T. Y., Lam C. W. K. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clinical Immunology . 2008;127(3):385&#x2013;393. doi: 10.1016/j.clim.2008.01.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2008.01.019</ArticleId><ArticleId IdType="pubmed">18373953</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivanov I. I., McKenzie B. S., Zhou L., et al. The orphan nuclear receptor ROR&#x3b3;t directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell . 2006;126(6):1121&#x2013;1133. doi: 10.1016/j.cell.2006.07.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2006.07.035</ArticleId><ArticleId IdType="pubmed">16990136</ArticleId></ArticleIdList></Reference><Reference><Citation>Crisp&#xed;n J. C., Apostolidis S. A., Rosetti F., et al. Cutting edge: protein phosphatase 2A confers susceptibility to autoimmune disease through an IL-17-dependent mechanism. The Journal of Immunology . 2012;188(8):3567&#x2013;3571. doi: 10.4049/jimmunol.1200143.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1200143</ArticleId><ArticleId IdType="pmc">PMC3324672</ArticleId><ArticleId IdType="pubmed">22422882</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolidis S. A., Rauen T., Hedrich C. M., Tsokos G. C., Crisp&#xed;n J. C. Protein phosphatase 2A enables expression of interleukin 17 (IL-17) through chromatin remodeling. Journal of Biological Chemistry . 2013;288(37):26775&#x2013;26784. doi: 10.1074/jbc.M113.483743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.483743</ArticleId><ArticleId IdType="pmc">PMC3772223</ArticleId><ArticleId IdType="pubmed">23918926</ArticleId></ArticleIdList></Reference><Reference><Citation>Woetmann A., Nielsen M., Christensen S. T., et al. Inhibition of protein phosphatase 2A induces serine/threonine phosphorylation, subcellular redistribution, and functional inhibition of STAT3. PNAS . 1999;96(19):10620&#x2013;10625. doi: 10.1073/pnas.96.19.10620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.96.19.10620</ArticleId><ArticleId IdType="pmc">PMC17932</ArticleId><ArticleId IdType="pubmed">10485875</ArticleId></ArticleIdList></Reference><Reference><Citation>Santarlasci V., Mazzoni A., Capone M., et al. Musculin inhibits human T-helper 17 cell response to interleukin 2 by controlling STAT5B activity. European Journal of Immunology . 2017;47(9):1427&#x2013;1442. doi: 10.1002/eji.201746996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201746996</ArticleId><ArticleId IdType="pubmed">28612433</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Q., Jin X., Zheng M., et al. Phosphatase PP2A is essential for TH17 differentiation. PNAS . 2018;116(3):982&#x2013;987. doi: 10.1073/pnas.1807484116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1807484116</ArticleId><ArticleId IdType="pmc">PMC6338861</ArticleId><ArticleId IdType="pubmed">30593560</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr T. K., Jameson S. C., Hogquist K. A. Positive and negative selection of T cells. Annual Review of Immunology . 2003;21:139&#x2013;176. doi: 10.1146/annurev.immunol.21.120601.141107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.21.120601.141107</ArticleId><ArticleId IdType="pubmed">12414722</ArticleId></ArticleIdList></Reference><Reference><Citation>Josefowicz S. Z., Lu L.-F., Rudensky A. Y. Regulatory T cells: mechanisms of differentiation and function. Annual Review of Immunology . 2012;30:531&#x2013;564. doi: 10.1146/annurev.immunol.25.022106.141623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.25.022106.141623</ArticleId><ArticleId IdType="pmc">PMC6066374</ArticleId><ArticleId IdType="pubmed">22224781</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyon M. F., Peters J., Glenister P. H., Ball S., Wright E. The scurfy mouse mutant has previously unrecognized hematological abnormalities and resembles Wiskott&#x2013;Aldrich syndrome. PNAS . 1990;87(7):2433&#x2013;2437. doi: 10.1073/pnas.87.7.2433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.87.7.2433</ArticleId><ArticleId IdType="pmc">PMC53703</ArticleId><ArticleId IdType="pubmed">2320565</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett C. L., Christie J., Ramsdell F., et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nature Genetics . 2001;27:20&#x2013;21. doi: 10.1038/83713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/83713</ArticleId><ArticleId IdType="pubmed">11137993</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine A. G., Arvey A., Jin W., Rudensky A. Y. Continuous requirement for the TCR in regulatory T cell function. Nature Immunology . 2014;15:1070&#x2013;1078. doi: 10.1038/ni.3004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3004</ArticleId><ArticleId IdType="pmc">PMC4205268</ArticleId><ArticleId IdType="pubmed">25263123</ArticleId></ArticleIdList></Reference><Reference><Citation>Salomon B., Lenschow D. J., Rhee L., et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity . 2000;12(4):431&#x2013;440. doi: 10.1016/S1074-7613(00)80195-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1074-7613(00)80195-8</ArticleId><ArticleId IdType="pubmed">10795741</ArticleId></ArticleIdList></Reference><Reference><Citation>Setoguchi R., Hori S., Takahashi T., Sakaguchi S. Homeostatic maintenance of natural Foxp3+ CD25+ CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. Journal of Experimental Medicine . 2005;201(5):723&#x2013;735. doi: 10.1084/jem.20041982.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20041982</ArticleId><ArticleId IdType="pmc">PMC2212841</ArticleId><ArticleId IdType="pubmed">15753206</ArticleId></ArticleIdList></Reference><Reference><Citation>Delgoffe G. M., Pollizzi K. N., Waickman A. T., et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nature Immunology . 2011;12:295&#x2013;303. doi: 10.1038/ni.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2005</ArticleId><ArticleId IdType="pmc">PMC3077821</ArticleId><ArticleId IdType="pubmed">21358638</ArticleId></ArticleIdList></Reference><Reference><Citation>Haxhinasto S., Mathis D., Benoist C. The AKT&#x2013;mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. Journal of Experimental Medicine . 2008;205(3):565&#x2013;574. doi: 10.1084/jem.20071477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20071477</ArticleId><ArticleId IdType="pmc">PMC2275380</ArticleId><ArticleId IdType="pubmed">18283119</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolidis S. A., Rodr&#xed;guez-Rodr&#xed;guez N., Su&#xe1;rez-Fueyo A., et al. Phosphatase PP2A is requisite for the function of regulatory T cells. Nature Immunology . 2016;17:556&#x2013;564. doi: 10.1038/ni.3390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3390</ArticleId><ArticleId IdType="pmc">PMC4837024</ArticleId><ArticleId IdType="pubmed">26974206</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Feng L., Li S., Long D., Shan J., Li Y. TGF-&#x3b2;1 maintains Foxp3 expression and inhibits glycolysis in natural regulatory T cells via PP2A-mediated suppression of mTOR signaling. Immunology Letters . 2020;226:31&#x2013;37. doi: 10.1016/j.imlet.2020.06.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imlet.2020.06.016</ArticleId><ArticleId IdType="pubmed">32598969</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding Y., Yu A., Tsokos G. C., Malek T. R. CD25 and protein phosphatase 2A cooperate to enhance IL-2R signaling in human regulatory T cells. The Journal of Immunology . 2019;203(1):93&#x2013;104. doi: 10.4049/jimmunol.1801570.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1801570</ArticleId><ArticleId IdType="pmc">PMC6581624</ArticleId><ArticleId IdType="pubmed">31085588</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharabi A., Li H., Kasper I. R., et al. PP2A enables IL-2 signaling by preserving IL-2R&#x3b2; chain expression during Treg development. JCI Insight . 2019;4(9) doi: 10.1172/jci.insight.126294.e126294</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.126294</ArticleId><ArticleId IdType="pmc">PMC6538314</ArticleId><ArticleId IdType="pubmed">30912768</ArticleId></ArticleIdList></Reference><Reference><Citation>Dardalhon V., Awasthi A., Kwon H., et al. IL-4 inhibits TGF-&#x3b2;-induced Foxp3+ T cells and, together with TGF-&#x3b2;, generates IL-9+ IL-10+ Foxp3&#x2212; effector T cells. Nature Immunology . 2008;9:1347&#x2013;1355. doi: 10.1038/ni.1677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1677</ArticleId><ArticleId IdType="pmc">PMC2999006</ArticleId><ArticleId IdType="pubmed">18997793</ArticleId></ArticleIdList></Reference><Reference><Citation>Veldhoen M., Uyttenhove C., van Snick J., et al. Transforming growth factor-&#x3b2; &#x2018;reprograms&#x2019; the differentiation of T helper 2 cells and promotes an interleukin 9&#x2013;producing subset. Nature Immunology . 2008;9:1341&#x2013;1346. doi: 10.1038/ni.1659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1659</ArticleId><ArticleId IdType="pubmed">18931678</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilhelm C., Hirota K., Stieglitz B., et al. An IL-9 fate reporter demonstrates the induction of an innate IL-9 response in lung inflammation. Nature Immunology . 2011;12:1071&#x2013;1077. doi: 10.1038/ni.2133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2133</ArticleId><ArticleId IdType="pmc">PMC3198843</ArticleId><ArticleId IdType="pubmed">21983833</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y., Hong S., Li H., et al. Th9 cells promote antitumor immune responses in vivo. The Journal of Clinical Investigation . 2012;122(11):4160&#x2013;4171. doi: 10.1172/JCI65459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI65459</ArticleId><ArticleId IdType="pmc">PMC3484462</ArticleId><ArticleId IdType="pubmed">23064366</ArticleId></ArticleIdList></Reference><Reference><Citation>Purwar R., Schlapbach C., Xiao S., et al. Robust tumor immunity to melanoma mediated by interleukin-9&#x2014;producing T cells. Nature Medicine . 2012;18:1248&#x2013;1253. doi: 10.1038/nm.2856.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2856</ArticleId><ArticleId IdType="pmc">PMC3518666</ArticleId><ArticleId IdType="pubmed">22772464</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan M. H. The transcription factor network in Th9 cells. Seminars in Immunopathology . 2017;39:11&#x2013;20. doi: 10.1007/s00281-016-0600-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-016-0600-2</ArticleId><ArticleId IdType="pmc">PMC5225158</ArticleId><ArticleId IdType="pubmed">27837254</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy S., Rizvi Z. A., Clarke A. J., et al. EGFR-HIF1&#x3b1; signaling positively regulates the differentiation of IL-9 producing T helper cells. Nature Communications . 2021;12 doi: 10.1038/s41467-021-23042-x.3182</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-23042-x</ArticleId><ArticleId IdType="pmc">PMC8169867</ArticleId><ArticleId IdType="pubmed">34075041</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy S., Goel R., Aggarwal S., Asthana S., Yadav A. K., Awasthi A. Proteome analysis revealed the essential functions of protein phosphatase PP2A in the induction of Th9 cells. Scientific Reports . 2020;10 doi: 10.1038/s41598-020-67845-2.10992</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-67845-2</ArticleId><ArticleId IdType="pmc">PMC7335106</ArticleId><ArticleId IdType="pubmed">32620893</ArticleId></ArticleIdList></Reference><Reference><Citation>Mumby M. PP2A: unveiling a reluctant tumor suppressor. Cell . 2007;130(1):21&#x2013;24. doi: 10.1016/j.cell.2007.06.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.06.034</ArticleId><ArticleId IdType="pubmed">17632053</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsokos G. C. Systemic lupus erythematosus. The New England Journal of Medicine . 2011;365:2110&#x2013;2121. doi: 10.1056/NEJMra1100359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1100359</ArticleId><ArticleId IdType="pubmed">22129255</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark A. R., Ohlmeyer M. Protein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration. Pharmacology &amp; Therapeutics . 2019;201:181&#x2013;201. doi: 10.1016/j.pharmthera.2019.05.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2019.05.016</ArticleId><ArticleId IdType="pmc">PMC6700395</ArticleId><ArticleId IdType="pubmed">31158394</ArticleId></ArticleIdList></Reference><Reference><Citation>Taymans J.-M., Baekelandt V. Phosphatases of &#x3b1;-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism. Frontiers in Genetics . 2014;5 doi: 10.3389/fgene.2014.00382.382</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2014.00382</ArticleId><ArticleId IdType="pmc">PMC4224088</ArticleId><ArticleId IdType="pubmed">25426138</ArticleId></ArticleIdList></Reference><Reference><Citation>Park H.-J., Lee K.-W., Park E. S., et al. Dysregulation of protein phosphatase 2A in parkinson disease and dementia with lewy bodies. Annals of Clinical and Translational Neurology . 2016;3(10):769&#x2013;780. doi: 10.1002/acn3.337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.337</ArticleId><ArticleId IdType="pmc">PMC5048387</ArticleId><ArticleId IdType="pubmed">27752512</ArticleId></ArticleIdList></Reference><Reference><Citation>Voronkov M., Braithwaite S. P., Stock J. B. Phosphoprotein phosphatase 2A: a novel druggable target for Alzheimer&#x2019;s disease. Future Medicinal Chemistry . 2011;3(7):821&#x2013;833. doi: 10.4155/fmc.11.47.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/fmc.11.47</ArticleId><ArticleId IdType="pmc">PMC3292348</ArticleId><ArticleId IdType="pubmed">21644827</ArticleId></ArticleIdList></Reference><Reference><Citation>Sontag J.-M., Sontag E. Protein phosphatase 2A dysfunction in Alzheimer&#x2019;s disease. Frontiers in Molecular Neuroscience . 2014;7 doi: 10.3389/fnmol.2014.00016.16</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2014.00016</ArticleId><ArticleId IdType="pmc">PMC3949405</ArticleId><ArticleId IdType="pubmed">24653673</ArticleId></ArticleIdList></Reference><Reference><Citation>Papon M.-A., El Khoury N. B., Marcouiller F., et al. Deregulation of protein phosphatase 2A and hyperphosphorylation of &#x3c4; protein following onset of diabetes in NOD mice. Diabetes . 2013;62(2):609&#x2013;617. doi: 10.2337/db12-0187.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db12-0187</ArticleId><ArticleId IdType="pmc">PMC3554372</ArticleId><ArticleId IdType="pubmed">22961084</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugi S., Imamura T., Maegawa H., et al. Protein phosphatase 2A negatively regulates insulin&#x2019;s metabolic signaling pathway by inhibiting Akt (protein kinase B) activity in 3T3-L1 adipocytes. Molecular and Cellular Biology . 2004;24(19):8778&#x2013;8789. doi: 10.1128/MCB.24.19.8778-8789.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.24.19.8778-8789.2004</ArticleId><ArticleId IdType="pmc">PMC516764</ArticleId><ArticleId IdType="pubmed">15367694</ArticleId></ArticleIdList></Reference><Reference><Citation>Arora D. K., Machhadieh B., Matti A., Wadzinski B. E., Ramanadham S., Kowluru A. High glucose exposure promotes activation of protein phosphatase 2A in rodent islets and INS-1 832/13 &#x3b2;-cells by increasing the posttranslational carboxylmethylation of its catalytic subunit. Endocrinology . 2014;155(2):380&#x2013;391. doi: 10.1210/en.2013-1773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/en.2013-1773</ArticleId><ArticleId IdType="pmc">PMC3891936</ArticleId><ArticleId IdType="pubmed">24265448</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagao M., Shima H., Nakayasu M., Sugimura T. Protein serine/threonine phosphatases as binding proteins for okadaic acid. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis . 1995;333(1-2):173&#x2013;179. doi: 10.1016/0027-5107(95)00143-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0027-5107(95)00143-3</ArticleId><ArticleId IdType="pubmed">8538625</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell K. S., Auger K. R., Hemmings B. A., Roberts T. M., Pallas D. C. Identification of regions in polyomavirus middle T and small t antigens important for association with protein phosphatase 2A. Journal of Virology . 1995;69(6):3721&#x2013;3728. doi: 10.1128/jvi.69.6.3721-3728.1995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.69.6.3721-3728.1995</ArticleId><ArticleId IdType="pmc">PMC189088</ArticleId><ArticleId IdType="pubmed">7538174</ArticleId></ArticleIdList></Reference><Reference><Citation>Neviani P., Santhanam R., Trotta R., et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell . 2005;8(5):355&#x2013;368. doi: 10.1016/j.ccr.2005.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccr.2005.10.015</ArticleId><ArticleId IdType="pubmed">16286244</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;ckelman C., Koskensalo S., Hagstr&#xf6;m J., Lundin M., Ristim&#xe4;ki A., Haglund C. CIP2A overexpression is associated with c-Myc expression in colorectal cancer. Cancer Biology &amp; Therapy . 2012;13(5):289&#x2013;295. doi: 10.4161/cbt.18922.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/cbt.18922</ArticleId><ArticleId IdType="pubmed">22310977</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaarala M. H., V&#xe4;is&#xe4;nen M.-R., Ristim&#xe4;ki A. CIP2A expression is increased in prostate cancer. Journal of Experimental &amp; Clinical Cancer Research . 2010;29 doi: 10.1186/1756-9966-29-136.136</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1756-9966-29-136</ArticleId><ArticleId IdType="pmc">PMC2984408</ArticleId><ArticleId IdType="pubmed">20964854</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Li W., Li L., Yu X., Jia J., Chen C. CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation. International Journal of Laboratory Hematology . 2011;33(3):290&#x2013;298. doi: 10.1111/j.1751-553X.2010.01288.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1751-553X.2010.01288.x</ArticleId><ArticleId IdType="pubmed">21219591</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma P., Wagner K., Wolchok J. D., Allison J. P. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nature Reviews Cancer . 2011;11:805&#x2013;812. doi: 10.1038/nrc3153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc3153</ArticleId><ArticleId IdType="pmc">PMC3426440</ArticleId><ArticleId IdType="pubmed">22020206</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma P., Allison J. P. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell . 2015;161(2):205&#x2013;214. doi: 10.1016/j.cell.2015.03.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.03.030</ArticleId><ArticleId IdType="pmc">PMC5905674</ArticleId><ArticleId IdType="pubmed">25860605</ArticleId></ArticleIdList></Reference><Reference><Citation>Topalian S. L., Drake C. G., Pardoll D. M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell . 2015;27(4):450&#x2013;461. doi: 10.1016/j.ccell.2015.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2015.03.001</ArticleId><ArticleId IdType="pmc">PMC4400238</ArticleId><ArticleId IdType="pubmed">25858804</ArticleId></ArticleIdList></Reference><Reference><Citation>Wohlfert E. A., Clark R. B. &#x2018;Vive la R&#xe9;sistance!&#x2019;&#x2014;the PI3K&#x2013;Akt pathway can determine target sensitivity to regulatory T cell suppression. Trends in Immunology . 2007;28(4):154&#x2013;160. doi: 10.1016/j.it.2007.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2007.02.003</ArticleId><ArticleId IdType="pubmed">17329168</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercadante E. R., Lorenz U. M. Breaking free of control: how conventional T cells overcome regulatory T cell suppression. Frontiers in Immunology . 2016;7 doi: 10.3389/fimmu.2016.00193.193</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2016.00193</ArticleId><ArticleId IdType="pmc">PMC4870238</ArticleId><ArticleId IdType="pubmed">27242798</ArticleId></ArticleIdList></Reference><Reference><Citation>C&#xf4;me C., Cvrljevic A., Khan M. M., et al. CIP2A promotes T-cell activation and immune response to Listeria monocytogenes Infection. PLOS ONE . 2016;11(4) doi: 10.1371/journal.pone.0152996.e0152996</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0152996</ArticleId><ArticleId IdType="pmc">PMC4839633</ArticleId><ArticleId IdType="pubmed">27100879</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazhar S., Taylor S. E., Sangodkar J., Narla G. Targeting PP2A in cancer: combination therapies. Biochimica et Biophysica Acta (BBA)&#x2014;Molecular Cell Research . 2019;1866(1):51&#x2013;63. doi: 10.1016/j.bbamcr.2018.08.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2018.08.020</ArticleId><ArticleId IdType="pmc">PMC6436821</ArticleId><ArticleId IdType="pubmed">30401535</ArticleId></ArticleIdList></Reference><Reference><Citation>Remmerie M., Janssens V. PP2A: a promising biomarker and therapeutic target in endometrial cancer. Frontiers in Oncology . 2019;9 doi: 10.3389/fonc.2019.00462.462</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2019.00462</ArticleId><ArticleId IdType="pmc">PMC6558005</ArticleId><ArticleId IdType="pubmed">31214504</ArticleId></ArticleIdList></Reference><Reference><Citation>Janghorban M., Farrell A. S., Allen-Petersen B. L., et al. Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer. PNAS . 2014;111(25):9157&#x2013;9162. doi: 10.1073/pnas.1317630111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1317630111</ArticleId><ArticleId IdType="pmc">PMC4078832</ArticleId><ArticleId IdType="pubmed">24927563</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsiari C. G., Kyttaris V. C., Juang Y.-T., Tsokos G. C. Protein phosphatase 2A is a negative regulator of IL-2 production in patients with systemic lupus erythematosus. The Journal of Clinical Investigation . 2005;115(11):3193&#x2013;3204. doi: 10.1172/JCI24895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI24895</ArticleId><ArticleId IdType="pmc">PMC1253625</ArticleId><ArticleId IdType="pubmed">16224536</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunahori K., Juang Y.-T., Kyttaris V. C., Tsokos G. C. Promoter hypomethylation results in increased expression of protein phosphatase 2A in T cells from patients with systemic lupus erythematosus. The Journal of Immunology . 2011;186(7):4508&#x2013;4517. doi: 10.4049/jimmunol.1000340.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1000340</ArticleId><ArticleId IdType="pmc">PMC3148941</ArticleId><ArticleId IdType="pubmed">21346232</ArticleId></ArticleIdList></Reference><Reference><Citation>Juang Y.-T., Wang Y., Jiang G., et al. PP2A Dephosphorylates Elf-1 and determines the expression of CD3&#x3b6; and FcR&#x3b3; in human systemic lupus erythematosus T cells. The Journal of Immunology . 2008;181(5):3658&#x2013;3664. doi: 10.4049/jimmunol.181.5.3658.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.181.5.3658</ArticleId><ArticleId IdType="pmc">PMC2662392</ArticleId><ArticleId IdType="pubmed">18714041</ArticleId></ArticleIdList></Reference><Reference><Citation>Nambiar M. P., Fisher C. U., Warke V. G., et al. Reconstitution of deficient T cell receptor &#x3b6; chain restores T cell signaling and augments T cell receptor/CD3-induced interleukin-2 production in patients with systemic lupus erythematosus. Arthritis &amp; Rheumatism . 2003;48(7):1948&#x2013;1955. doi: 10.1002/art.11072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.11072</ArticleId><ArticleId IdType="pubmed">12847689</ArticleId></ArticleIdList></Reference><Reference><Citation>Juang Y.-T., Rauen T., Wang Y., et al. Transcriptional activation of the cAMP-responsive modulator promoter in human T cells is regulated by protein phosphatase 2A-mediated dephosphorylation of SP-1 and reflects disease activity in patients with systemic lupus erythematosus. Journal of Biological Chemistry . 2011;286(3):1795&#x2013;1801. doi: 10.1074/jbc.M110.166785.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.166785</ArticleId><ArticleId IdType="pmc">PMC3023474</ArticleId><ArticleId IdType="pubmed">21097497</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunahori K., Nagpal K., Hedrich C. M., Mizui M., Fitzgerald L. M., Tsokos G. C. The catalytic subunit of protein phosphatase 2A (PP2Ac) promotes DNA hypomethylation by suppressing the phosphorylated mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase (MEK)/phosphorylated ERK/DNMT1 protein pathway in T-cells from controls and systemic lupus erythematosus patients. Journal of Biological Chemistry . 2013;288(30):21936&#x2013;21944. doi: 10.1074/jbc.M113.467266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.467266</ArticleId><ArticleId IdType="pmc">PMC3724648</ArticleId><ArticleId IdType="pubmed">23775084</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharabi A., Kasper I. R., Tsokos G. C. The serine/threonine protein phosphatase 2A controls autoimmunity. Clinical Immunology . 2018;186:38&#x2013;42. doi: 10.1016/j.clim.2017.07.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2017.07.012</ArticleId><ArticleId IdType="pmc">PMC5776067</ArticleId><ArticleId IdType="pubmed">28736280</ArticleId></ArticleIdList></Reference><Reference><Citation>McFarland H. F., Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nature Immunology . 2007;8:913&#x2013;919. doi: 10.1038/ni1507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni1507</ArticleId><ArticleId IdType="pubmed">17712344</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinkmann V., Billich A., Baumruker T., et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nature Reviews Drug Discovery . 2010;9:883&#x2013;897. doi: 10.1038/nrd3248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd3248</ArticleId><ArticleId IdType="pubmed">21031003</ArticleId></ArticleIdList></Reference><Reference><Citation>La Mantia L., Tramacere I., Firwana B., Pacchetti I., Palumbo R., Filippini G. Fingolimod for relapsing-remitting multiple sclerosis. Cochrane Database of Systematic Reviews . 2016;4 doi: 10.1002/14651858.CD009371.pub2.CD009371</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD009371.pub2</ArticleId><ArticleId IdType="pubmed">27091121</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka H., Sugahara K., Shimano K., et al. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cellular &amp; Molecular Immunology . 2005;2(6):439&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pubmed">16426494</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller H., Hofer S., Kaneider N., et al. The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells. European Journal of Immunology . 2005;35(2):533&#x2013;545. doi: 10.1002/eji.200425556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.200425556</ArticleId><ArticleId IdType="pubmed">15657952</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas K., Sehr T., Proschmann U., Rodriguez-Leal F. A., Haase R., Ziemssen T. Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation. Journal of Neuroinflammation . 2017;14 doi: 10.1186/s12974-017-0817-6.41</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-017-0817-6</ArticleId><ArticleId IdType="pmc">PMC5322645</ArticleId><ArticleId IdType="pubmed">28231856</ArticleId></ArticleIdList></Reference><Reference><Citation>Idzko M., Hammad H., van Nimwegen M., et al. Local application of FTY720 to the lung abrogates experimental asthma by altering dendritic cell function. The Journal of Clinical Investigation . 2006;116(11):2935&#x2013;2944. doi: 10.1172/JCI28295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI28295</ArticleId><ArticleId IdType="pmc">PMC1626118</ArticleId><ArticleId IdType="pubmed">17080194</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Connor C. M., Perl A., Leonard D., Sangodkar J., Narla G. Therapeutic targeting of PP2A. The International Journal of Biochemistry &amp; Cell Biology . 2018;96:182&#x2013;193. doi: 10.1016/j.biocel.2017.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biocel.2017.10.008</ArticleId><ArticleId IdType="pmc">PMC5927617</ArticleId><ArticleId IdType="pubmed">29107183</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung V., Mansfield A. S., Braiteh F., et al. Safety, tolerability, and preliminary activity of LB-100, an inhibitor of protein phosphatase 2A, in patients with relapsed solid tumors: an open-label, dose escalation, first-in-human, phase I trial. Clinical Cancer Research . 2017;23(13):3277&#x2013;3284. doi: 10.1158/1078-0432.CCR-16-2299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-16-2299</ArticleId><ArticleId IdType="pubmed">28039265</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronk H., Rosenblum J. S., Kung T., Zhuang Z. Targeting PP2A for cancer therapeutic modulation. Cancer Biology &amp; Medicine . 2022;19(10):1428&#x2013;1439. doi: 10.20892/j.issn.2095-3941.2022.0330.</Citation><ArticleIdList><ArticleId IdType="doi">10.20892/j.issn.2095-3941.2022.0330</ArticleId><ArticleId IdType="pmc">PMC9630519</ArticleId><ArticleId IdType="pubmed">36342229</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanford S. M., Bottini N. Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders. Nature Reviews Drug Discovery . 2023;22:273&#x2013;294. doi: 10.1038/s41573-022-00618-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-022-00618-w</ArticleId><ArticleId IdType="pmc">PMC9872771</ArticleId><ArticleId IdType="pubmed">36693907</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>